A compound of formula (I)

##STR00001##

or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants

There are described RORγ modulators of the formula (I),

##STR00001##

and formula (II)

##STR00002##

or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

The present invention relates to a novel phosphite compound represented by the formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a cycloalkyl group having 5 to 8 carbon atoms, an alkylcycloalkyl group having 6 to 12 carbon atoms, an aralkyl group having 7 to 12 carbon atoms, or an aryl group having 6 to 12 carbon atoms, a process for producing the same, and uses thereof as a stabilizer for an organic material.

The present invention relates to a novel phosphite compound represented by the formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a cycloalkyl group having 5 to 8 carbon atoms, an alkylcycloalkyl group having 6 to 12 carbon atoms, an aralkyl group having 7 to 12 carbon atoms, or an aryl group having 6 to 12 carbon atoms, a process for producing the same, and uses thereof as a stabilizer for an organic material.

The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. The compounds of this disclosure also relate to ##STR00001##
The use of these compounds as radio— and chemo—protectors is also described.

Bisphosphite ligands based on benzopinacol, and the use thereof in hydroformylation.

Compounds of the general formula

##STR00001##

are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.

Provided is a degradation inhibitor that delays the progress of the degradation reaction of 2ccPA and has an excellent stabilization effect by using a carbacyclic phosphatidic acid compound represented by formula (1):

##STR00001##

wherein R.sup.1 represents hydrogen, alkali metal, alkyl, arylalkyl, or aryl; bonds indicated by solid and dotted lines represent single or double bonds; wavy lines represent single bonds; and when the single bond is adjacent to a double bond, the steric configuration is E-configuration, Z-configuration, or any mixture thereof.

A lithium battery including: a cathode; an anode; and an electrolyte between the cathode and the anode, wherein the cathode includes a cathode active material represented by Formula 1,
Li.sub.xNi.sub.yM.sub.1−yO.sub.2-zA.sub.z  Formula 1 wherein 0.95≤x≤1.2, 0.75≤y≤0.98, and 0≤z<0.2, M is Al, Mg, Mn, Co, Fe, Cr, V, Ti, Cu, B, Ca, Zn, Zr, Nb, Mo, Sr, Sb, W, Bi, or a combination thereof, and A is an element having an oxidation number of −1, −2, or −3, wherein each element of M is independently present in an amount of 0.02≤y≤0.3, wherein a total content of M is 0.02≤y≤0.3;
and wherein the electrolyte includes a lithium salt, a non-aqueous solvent, and a diallyl compound represented by Formula 2, ##STR00001## wherein L.sub.1 and L.sub.2 are each independently a single bond, a C.sub.1-C.sub.20 alkylene group, or a substituted or unsubstituted C.sub.2-C.sub.20 alkenylene group.

The present invention relates to a process for resolution of Chlocyphos of Formula (I) to obtain corresponding (S)- or (R)-isomers. The present invention further relates to a process of obtaining (S)-Chlocyphos using (R)-(+)-α-methylbenzylamine and (R)-Chlocyphos using (S)-α-methylbenzylamine. The said resolution process provides the corresponding isomer with chiral purity more than 98%.

##STR00001##